Trigger primary data analysis for CERPASS clinical trial

Not delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced: 4 Nov 2021
Due: 31 Dec 2022
Checked: 1 Oct 2026

Deadline
Met
Late
Not met
Today

What the company said

“the primary data trigger expected in late 2022”

SourceReplimune Group, Inc. Form 8-K press release, 2021-11-04
FilingSEC filing index
Deadline as statedlate 2022
Deadline used31 Dec 2022, the last day of the stated period
TypeProject
Permanent referenceKI-C-2021-REPL-002634
Cite as https://keptindex.org/c/KI-C-2021-REPL-002634/ — this address never changes.

What we found

Evidence strength A What the grades mean

The company delayed the primary data analysis trigger for the CERPASS trial beyond the late 2022 deadline, rescheduling the expected topline data announcement to Q3 2023.

A
Replimune Group, Inc. 10-Q filed 2023-02-09 Regulatory filing · published 9 Feb 2023 · retrieved 1 Oct 2026 · kept permanently by the SEC · fingerprint 00ab5e0e3d55
“Topline data from the CERPASS trial is now expected to be announced in Q3 2023, due primarily to the decision to trigger the primary analysis at 40 weeks from last patient in” ✓ confirmed on the page

Market reaction: the shares moved -11.9% against the S&P 500 over the three sessions around the disclosure (8 Feb 2023 to 13 Feb 2023). What this measures

Checked 1 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

Deadline drift +181 days
2 versions

Version 1 · original · stated 4 Nov 2021

Deadline 31 Dec 2022 (“late 2022”) · wording expected
Version 2 · stated 4 Aug 2022

Deadline 30 Jun 2023 (“H1 2023”) · wording expected

“primary analysis data from this clinical trial is expected to be released in H1 2023.”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical readout
Indicative materiality: Medium rules
Action: Trigger
Deliverable: Primary data analysis trigger for CERPASS trial
Language: Expected (“expects”, “plans”)
In the company’s control: High
Specificity: High

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Replimune Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.